TY - JOUR
T1 - Posatirelin in the treatment of vascular dementia
T2 - A double-blind multicentre study vs placebo
AU - Parnetti, L.
AU - Ambrosoli, L.
AU - Agliati, G.
AU - Caratozzolo, P.
AU - Fossati, L.
AU - Frattola, L.
AU - Martucci, N.
AU - Murri, L.
AU - Nappi, G.
AU - Puca, F. M.
AU - Poli, A.
AU - Girardello, R.
AU - Senin, U.
PY - 1996
Y1 - 1996
N2 - Introduction - The usefulness of posatirelin (L-pyro-2-aminoadipyl-L-leucyl-1-prolinamide) , a synthetic peptide having modulatory activity on the monoaminergic and cholinergic systems and neurotrophic effects, was evaluated in vascular dementia. Patients and methods - A multicentre, parallel groups, double-blind clinical study vs placebo was carried out with patients suffering from probable vascular dementia according to the NINDS-AIREN criteria. The study consisted of a two-week run-in of a once daily, orally administered, placebo phase, followed by 12 weeks of intramuscular treatment with posatirelin 10 mg/ml or placebo given once a day and a follow-up after one month's withdrawal. Efficacy was assessed using the Gottries-Brane-Steen (GBS) Rating Scale for dementia, the Randt Memory Test and the Toulouse-Pieron Attention Test. Data were evaluated using analysis of variance and covariance. Results - As regards GBS scores, patients treated with posatirelin showed a significant improvement in intellectual performance; in orientation, motivation and memory as compared to controls. The improvement of memory performance was also confirmed by the acquisition score and memory index of the Randt Memory Test. At the-end of the follow-up period the differences between treatments were still maintained. Tolerability was good. Conclusions - The significant improvement observed in cognitive functions, attention and motivation of demented patients treated with posatirelin suggests the pootential usefulness of this drug in vascular dementia. Furthermore, the presence of a long-lasting effect after drug withdrawal suggests the possibility of administering the drug cyclically.
AB - Introduction - The usefulness of posatirelin (L-pyro-2-aminoadipyl-L-leucyl-1-prolinamide) , a synthetic peptide having modulatory activity on the monoaminergic and cholinergic systems and neurotrophic effects, was evaluated in vascular dementia. Patients and methods - A multicentre, parallel groups, double-blind clinical study vs placebo was carried out with patients suffering from probable vascular dementia according to the NINDS-AIREN criteria. The study consisted of a two-week run-in of a once daily, orally administered, placebo phase, followed by 12 weeks of intramuscular treatment with posatirelin 10 mg/ml or placebo given once a day and a follow-up after one month's withdrawal. Efficacy was assessed using the Gottries-Brane-Steen (GBS) Rating Scale for dementia, the Randt Memory Test and the Toulouse-Pieron Attention Test. Data were evaluated using analysis of variance and covariance. Results - As regards GBS scores, patients treated with posatirelin showed a significant improvement in intellectual performance; in orientation, motivation and memory as compared to controls. The improvement of memory performance was also confirmed by the acquisition score and memory index of the Randt Memory Test. At the-end of the follow-up period the differences between treatments were still maintained. Tolerability was good. Conclusions - The significant improvement observed in cognitive functions, attention and motivation of demented patients treated with posatirelin suggests the pootential usefulness of this drug in vascular dementia. Furthermore, the presence of a long-lasting effect after drug withdrawal suggests the possibility of administering the drug cyclically.
KW - GBS Rating Scale
KW - Posatirelin
KW - Psycobehavioural assessment
KW - Vascular dementia
UR - http://www.scopus.com/inward/record.url?scp=8944256877&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=8944256877&partnerID=8YFLogxK
M3 - Article
C2 - 8836309
AN - SCOPUS:8944256877
VL - 93
SP - 456
EP - 463
JO - Acta Neurologica Scandinavica
JF - Acta Neurologica Scandinavica
SN - 0001-6314
IS - 6
ER -